Pneumococcal conjugate vaccines (PCVs)
- Minimum age: 6 weeks
- Both PCV10 and PCV13 are licensed for children from 6 weeks to 5 years of age.
- Additionally, PCV13 is licensed for the prevention of pneumococcal diseases in adults > 50
years of age.
- Primary schedule (for both PCV10 and PCV13): 3 primary doses at 6, 10, and 14 weeks with
a booster at age 12 through 15 months.
- Administer 1 dose of PCV13 or PCV10 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.
- For PCV 13: Catch-up in 6–12 months: 2 doses 4 weeks apart and 1 booster;
12–23 months: 2 doses 8 weeks apart;
24 months and above: Single dose
- For PCV10: Catch up in 6–12 months: 2 doses 4 weeks apart and 1 booster;
12 months to 5 years: 2 doses 8 weeks apart
- Vaccination of persons with high-risk conditions: PCV and pneumococcal polysaccharide
vaccine [PPSV] both are used in certain high-risk group of children.
- For children aged 24 through 71 months with certain underlying medical conditions,
administer 1 dose of PCV13 if 3 doses of PCV were received previously, or
administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses
of PCV were received previously.
- A single dose of PCV13 may be administered to previously unvaccinated children aged 6
through 18 years who have
- anatomic or functional asplenia (including sickle cell disease),
- HIV infection or an immunocompromising condition,
- cochlear implant or cerebrospinal fluid leak.
- Administer PPSV23 at least 8 weeks after the last dose of PCV to children aged 2 years or
older with certain underlying medical conditions.